MR-Guided Transurethral Ultrasound Ablation (TULSA)-An Emerging Minimally Invasive Treatment Option for Localised Prostate Cancer.
Fiche publication
Date publication
mars 2024
Journal
Cardiovascular and interventional radiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GANGI Afshin, Pr LANG Hervé, Dr GARNON Julien, Dr TRICARD Thibault
Tous les auteurs :
Fung KFK, Cazzato RL, Tricard T, Marini PDE, Bertucci G, Autrusseau PA, Koch G, Weiss J, Garnon J, Lang H, Gangi A
Lien Pubmed
Résumé
The optimal treatment strategy for men with localised prostatic cancer of low and intermediate risk is an actively evolving field. It is important to strike a balance between maximal oncological control and minimal treatment-related complications, which helps preserve the patients' quality of life. MR-guided transurethral ultrasound ablation (TULSA) has emerged as a minimally invasive treatment option for this group of patients. This article aims to provide of a background on TULSA technology, a step-by-step procedural guide of MR-guided TULSA and to summarise the current evidence of TULSA in management of localised prostatic cancer, as well as other potential indications.
Mots clés
Ablation, Interventional oncology, Magnetic resonance, Prostate cancer
Référence
Cardiovasc Intervent Radiol. 2024 03 15;: